FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:984-996 March 29, 2001 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Drug interactions are an important factor in the treatment of patients with human immunodeficiency virus (HIV) infection. The complexity of current drug regimens for such patients requires that clinicians recognize and manage drug interactions. Antiretroviral drug regimens typically consist of three or four antiretroviral drugs but may include even more. In addition, patients may receive other drugs for supportive care, treatment of opportunistic infections, and immunomodulation, as well as alternative drugs obtained from health care providers other than their primary provider. Drug interactions are often unavoidable in HIV-infected patients because of the drug classes involved and the number of drugs . . . [Full Text of this Article]

Mechanisms of Drug Interactions

Metabolic Interactions

Intestinal Metabolism and P-Glycoprotein

Drug Absorption

Renal Elimination

Predicting Drug Interactions

Nucleoside-Analogue Reverse-Transcriptase Inhibitors

Non-Nucleoside Reverse-Transcriptase Inhibitors

HIV-Protease Inhibitors

Drugs for Opportunistic Infections

Special Issues

Alternative Therapies

Drug–Cytokine Interactions

Role of Therapeutic Drug Monitoring

Management of Drug Interactions

Source Information

From the Clinical Pharmacokinetics Research Laboratory, Department of Pharmacy, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, Md. (S.C.P.); and the Clinical Investigation Unit and Ottawa Hospital Research Institute, Ottawa Hospital, Ottawa, Ont., Canada (K.D.G.).

Address reprint requests to Dr. Piscitelli at Virco Laboratories, Johns Hopkins Bayview Campus, Alpha Ctr., 3rd Fl., 5210 Eastern Ave., Baltimore, MD 21224.

References

This article has been cited by other articles:

• Colucci, P., Pottage, J. C., Robison, H., Turgeon, J., Schurmann, D., Hoepelman, I. M., Ducharme, M. P. (2009). Multiple-Dose Pharmacokinetic Behavior of Elvucitabine, a Nucleoside Reverse Transcriptase Inhibitor, Administered over 21 Days with Lopinavir-Ritonavir in Human Immunodeficiency Virus Type 1-Infected Subjects. Antimicrob. Agents Chemother. 53: 662-669 [Abstract] [Full Text]  
• Rhee, M. S., Greenblatt, D. J. (2008). Pharmacologic Consideration for the Use of Antiretroviral Agents in the Elderly. J Clin Pharmacol 48: 1212-1225 [Abstract] [Full Text]  
• Bailey, A. C., Fisher, M. (2008). Current use of antiretroviral treatment. Br Med Bull 87: 175-192 [Abstract] [Full Text]  
• Yasuda, K., Ranade, A., Venkataramanan, R., Strom, S., Chupka, J., Ekins, S., Schuetz, E., Bachmann, K. (2008). A Comprehensive in Vitro and in Silico Analysis of Antibiotics That Activate Pregnane X Receptor and Induce CYP3A4 in Liver and Intestine. Drug Metab. Dispos. 36: 1689-1697 [Abstract] [Full Text]  
• Ji, P., Damle, B., Xie, J., Unger, S. E., Grasela, D. M., Kaul, S. (2008). Pharmacokinetic Interaction Between Efavirenz and Carbamazepine After Multiple-Dose Administration in Healthy Subjects. J Clin Pharmacol 48: 948-956 [Abstract] [Full Text]  
• Foisy, M. M, Yakiwchuk, E. M, Hughes, C. A (2008). Induction Effects of Ritonavir: Implications for Drug Interactions. The Annals of Pharmacotherapy 42: 1048-1059 [Abstract] [Full Text]  
• Iwamoto, M., Kassahun, K., Troyer, M. D., Hanley, W. D., Lu, P., Rhoton, A., Petry, A. S., Ghosh, K., Mangin, E., DeNoia, E. P., Wenning, L. A., Stone, J. A., Gottesdiener, K. M., Wagner, J. A. (2008). Lack of a Pharmacokinetic Effect of Raltegravir on Midazolam: In Vitro/In Vivo Correlation. J Clin Pharmacol 48: 209-214 [Abstract] [Full Text]  
• Mok, S., Minson, Q. (2008). Drug-related problems in hospitalized patients with HIV infection. Am J Health Syst Pharm 65: 55-59 [Abstract] [Full Text]  
• (2007). Norwegian Scholarships for the Master's and Doctoral Programs. Gender Technology and Development 11: 417-427  
• Weiss, J., Theile, D., Ketabi-Kiyanvash, N., Lindenmaier, H., Haefeli, W. E. (2007). Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by Nucleoside, Nucleotide, and Non-Nucleoside Reverse Transcriptase Inhibitors. Drug Metab. Dispos. 35: 340-344 [Abstract] [Full Text]  
• Sekar, V. J., Lefebvre, E., De Paepe, E., De Marez, T., De Pauw, M., Parys, W., Hoetelmans, R. M. W. (2007). Pharmacokinetic Interaction between Darunavir Boosted with Ritonavir and Omeprazole or Ranitidine in Human Immunodeficiency Virus-Negative Healthy Volunteers. Antimicrob. Agents Chemother. 51: 958-961 [Abstract] [Full Text]  
• Weiss, J., Rose, J., Storch, C. H., Ketabi-Kiyanvash, N., Sauer, A., Haefeli, W. E., Efferth, T. (2007). Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother 59: 238-245 [Abstract] [Full Text]  
• Fulco, P. P., Vora, U. B, Bearman, G. M. (2006). Acid Suppressive Therapy and the Effects on Protease Inhibitors. The Annals of Pharmacotherapy 40: 1974-1983 [Abstract] [Full Text]  
• Corbett, A. H., Patterson, K. B., Tien, H.-C., Kalvass, L. A., Eron, J. J., Ngo, L. T., Lim, M. L., Kashuba, A. D. M. (2006). Dose Separation Does Not Overcome the Pharmacokinetic Interaction between Fosamprenavir and Lopinavir/Ritonavir.. Antimicrob. Agents Chemother. 50: 2756-2761 [Abstract] [Full Text]  
• Oette, M., Kroidl, A., Gobels, K., Stabbert, A., Menge, M., Sagir, A., Kuschak, D., O'Hanley, T., Bode, J. G., Haussinger, D. (2006). Predictors of short-term success of antiretroviral therapy in HIV infection. J Antimicrob Chemother 58: 147-153 [Abstract] [Full Text]  
• Bates, D. E, Herman, R. J (2006). Carbamazepine Toxicity Induced by Lopinavir/Ritonavir and Nelfinavir. The Annals of Pharmacotherapy 40: 1190-1195 [Abstract] [Full Text]  
• Uko, S., Soghier, L. M., Vega, M., Marsh, J., Reinersman, G. T., Herring, L., Dave, V. A., Nafday, S., Brion, L. P. (2006). Targeted Short-Term Fluconazole Prophylaxis Among Very Low Birth Weight and Extremely Low Birth Weight Infants. Pediatrics 117: 1243-1252 [Abstract] [Full Text]  
• Winston, A., Boffito, M. (2005). The management of HIV-1 protease inhibitor pharmacokinetic interactions. J Antimicrob Chemother 56: 1-5 [Abstract] [Full Text]  
• Ribera, E., Lopez, R. M., Diaz, M., Pou, L., Ruiz, L., Falco, V., Crespo, M., Azuaje, C., Ruiz, I., Ocana, I., Clotet, B., Pahissa, A. (2004). Steady-State Pharmacokinetics of a Double-Boosting Regimen of Saquinavir Soft Gel plus Lopinavir plus Minidose Ritonavir in Human Immunodeficiency Virus-Infected Adults. Antimicrob. Agents Chemother. 48: 4256-4262 [Abstract] [Full Text]  
• Mitchell, H S, Stephens, E (2004). Contraception choice for HIV positive women. Sex. Transm. Infect. 80: 167-173 [Abstract] [Full Text]  
• la Porte, C. J. L., Colbers, E. P. H., Bertz, R., Voncken, D. S., Wikstrom, K., Boeree, M. J., Koopmans, P. P., Hekster, Y. A., Burger, D. M. (2004). Pharmacokinetics of Adjusted-Dose Lopinavir-Ritonavir Combined with Rifampin in Healthy Volunteers. Antimicrob. Agents Chemother. 48: 1553-1560 [Abstract] [Full Text]  
• Abrams, D. I., Hilton, J. F., Leiser, R. J., Shade, S. B., Elbeik, T. A., Aweeka, F. T., Benowitz, N. L., Bredt, B. M., Kosel, B., Aberg, J. A., Deeks, S. G., Mitchell, T. F., Mulligan, K., Bacchetti, P., McCune, J. M., Schambelan, M. (2003). Short-Term Effects of Cannabinoids in Patients with HIV-1 Infection: A Randomized, Placebo-Controlled Clinical Trial. ANN INTERN MED 139: 258-266 [Abstract] [Full Text]  
• Selwyn, P. A., Forstein, M. (2003). Overcoming the False Dichotomy of Curative vs Palliative Care for Late-Stage HIV/AIDS: "Let Me Live the Way I Want to Live, Until I Can't". JAMA 290: 806-814 [Abstract] [Full Text]  
• Bergshoeff, A. S, Wolfs, T. F., Geelen, S. P., Burger, D. M (2003). Ritonavir-Enhanced Pharmacokinetics of Nelfinavir/M8 During Rifampin Use. The Annals of Pharmacotherapy 37: 521-525 [Abstract] [Full Text]  
• Greenblatt, D. J., von Moltke, L. L., Harmatz, J. S., Fogelman, S. M., Chen, G., Graf, J. A., Mertzanis, P., Byron, S., Culm, K. E., Granda, B. W., Daily, J. P., Shader, R. I. (2003). Short-Term Exposure to Low-Dose Ritonavir Impairs Clearance and Enhances Adverse Effects of Trazodone. J Clin Pharmacol 43: 414-422 [Abstract] [Full Text]  
• Boffito, M., Carriero, P., Trentini, L., Raiteri, R., Bonora, S., Sinicco, A., Reynolds, H. E., Hoggard, P. G., Back, D. J., Di Perri, G. (2002). Pharmacokinetics of saquinavir co-administered with cimetidine. J Antimicrob Chemother 50: 1081-1084 [Abstract] [Full Text]  
• Masur, H. (2002). Acquired Immunodeficiency Syndrome in the Intensive Care Unit: Will Human Immunodeficiency Virus-related Admissions Continue to Decline?. Am. J. Respir. Crit. Care Med. 166: 258-259 [Full Text]  
• Dussault, I., Lin, M., Hollister, K., Wang, E. H., Synold, T. W., Forman, B. M. (2001). Peptide Mimetic HIV Protease Inhibitors Are Ligands for the Orphan Receptor SXR. J. Biol. Chem. 276: 33309-33312 [Abstract] [Full Text]